Skip to main content

Theralase Technologies Inc.(TLT-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.228
Day High0.260
Open:0.255
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Theralase(R) Announces $4 Million Brokered LIFE Offering
Newsfile
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Newsfile
Upcoming Meeting Dates - May 4, 2026
Newsfile
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Newsfile
Theralase(R) Closes $CAN 2.66 Million Financing
Newsfile
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Newsfile
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Newsfile
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Newsfile
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Newsfile
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Newsfile
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Newsfile
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Newsfile
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Newsfile
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
AllPennyStocks.com
New Bladder Cancer Collaboration Sparks Sharp Rally in This Micro Cap Stock
New Bladder Cancer Collaboration Sparks Sharp Rally in This Micro Cap Stock
Newsfile
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Newsfile
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Newsfile
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Newsfile
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Profile

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.